Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: GlobeNewswire
CRANBURY, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake. ATB200 is the biologic component of the Company’s investigational Pompe treatment paradigm AT-GAA, which consists of ATB200 co-administered with AT2221, a pharmacological chaperone. The first U.S. patent No. 10,208,299 reflects composition of matter for highly potent rhGAA with enhanced carbohydrates. The second U.S. patent No. 10,227,577 covers the methods for making ATB200. The patents are set to expire in 2035 and 2036, respectively. Amicus is pursuing corresponding patent applications in other regions and countries, including Europe and Japan. “These newly issued U.S. pate
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
- Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 2/28/24 - Beat
FOLD
Sec Filings
- 3/19/24 - Form 4
- 3/15/24 - Form 4/A
- 3/15/24 - Form 4/A
- FOLD's page on the SEC website